in EPCLUSA
What it isHCV NS5A inhibitor, given with sofosbuvir; chronic hepatitis C.
Why this onePangenotypic, so genotyping is unnecessary, with cure rates above 95%.
What limits itHepatitis B reactivation, so B status must be known first. Amiodarone with sofosbuvir causes severe bradycardia; acid suppressants reduce absorption.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Chronic HCV genotype 1–6, no cirrhosis or compensated cirrhosis (Child-Pugh A) | Adults & peds ≥6 y or ≥17 kg | EPCLUSA (sofosbuvir 400 mg / velpatasvir 100 mg) QD ×12 weeks | 1 tablet QD ×12 weeks | |
| Chronic HCV, decompensated cirrhosis (Child-Pugh B or C) | Adults | EPCLUSA + ribavirin QD ×12 weeks | 1 tablet QD + ribavirin ×12 weeks | |
| Chronic HCV genotype 1–6 | Peds ≥6 y or ≥17 kg | Weight-based (per label Table 2) QD ×12 weeks | Weight-based QD |
Renal No dosage adjustment needed, including ESRD on dialysis.
Hepatic Decompensated cirrhosis (Child-Pugh B/C): add ribavirin.
Pregnancy With ribavirin: contraindicated in pregnancy; EPCLUSA alone — no adequate human data.
Lactation Unknown whether present in human milk.
⚠ BOXED WARNING
Principal riskHepatitis B reactivation; amiodarone causes severe bradycardia

Open Velpatasvir in the interactive console ↗
